Angiogenic gene therapy in cardiovascular diseases: Dream or vision?

European Heart Journal

Volumn 38, Issue 18, 2017, Pages 1365-1371

  Ylä Herttuala, Seppo ^a,b   Bridges, Charles ^c   Katz, Michael G ^c   Korpisalo, Petra ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Coronary heart disease; Gene delivery Growth factors; Gene therapy; Heart failure; Peripheral arterial disease

Indexed keywords

ADENOVIRUS VECTOR; FIBROBLAST GROWTH FACTOR; SCATTER FACTOR; VASCULOTROPIN; ANGIOGENIC FACTOR;

ANGIOGENIC GENE THERAPY; CARDIOVASCULAR DISEASE; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; PATIENT SELECTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; VIRAL GENE THERAPY; CLINICAL TRIAL (TOPIC); FORECASTING; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; HEART MUSCLE ISCHEMIA; PERIPHERAL VASCULAR DISEASE; PROCEDURES;

ANGIOGENESIS INDUCING AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; FORECASTING; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HEART FAILURE; HUMANS; MYOCARDIAL ISCHEMIA; PATIENT SELECTION; PERIPHERAL VASCULAR DISEASES; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 85019723959     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehw547     Document Type: Review

References (50)

1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER III, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB. American heart association statistics committee and stroke statistics subcommittee. heart disease and stroke statistics - 2016 Update. Circulation 2015;131:e29-322.
2. Townsend N, Nichols M, Scarborough P, Rayner M. Cardiovascular disease in Europe - Epidemiological update 2015. Eur. Heart J 2015;36:2696-2705.
3. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999;5:1359-1364.
4. Yla-Herttuala S, Rissanen TT, Vajanto I, Hartikainen J. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 2007;49:1015-1026.
5. Rissanen TT, Yla-Herttuala S. Current status of cardiovascular gene therapy. Mol Ther 2007;15:1233-1247.
6. Markkanen JE, Rissanen TT, Kivelä A, Ylä-Herttuala S. Growth factor-induced therapeutic angiogenesis and arteriogenesis in the heart-gene therapy. Cardiovasc Res 2005;65:656-664.
7. Henry TD, Satran D, Jolicoeur EM. Treatment of refractory angina in patients not suitable for revascularization. Nat Rev Cardiol 2014;11:78-95.
8. Henry TD, Satran D, Hodges JS, Johnson RK, Poulose AK, Campbell AR, Garberich RF, Bart BA, Olson RE, Boisjolie CR, Harvey KL, Arndt TL, Traverse JH. Long-term survival in patients with refractory angina. Eur Heart J 2013;34:2683-2688.
9. Naldini L. Gene therapy returns to centre stage. Nature 2015;526:351-360.
10. Kastrup J, Jorgensen E, Ruck A, Tagil K, Glogar D, Ruzyllo W, Botker HE, Dudek D, Drvota V, Hesse B, Thuesen L, Blomberg P, Gyongyosi M, Sylven C. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebocontrolled study: the Euroinject One trial. J Am CollCardiol 2005;45:982-988.
11. Hedman M, Hartikainen J, Syvanne M, Stjernvall J, Hedman A, Kivela A, Vanninen E, Mussalo H, Kauppila E, Simula S, Narvanen O, Rantala A, Peuhkurinen K, Nieminen MS, Laakso M, Yla-Herttuala S. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio. Circulation 2003;107:2677-2683.
12. Stewart DJ, Kutryk MJB, Fitchett D, Freeman M, Camack N, Su Y, Siega AD, Bilodeau L, Burton JR, Proulx G, Radhakrishnan S. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol Ther 2009;17:1109-1115.
13. Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman GW, Hachamovitch R, Szulc M, Kligfield PD, Okin PM, Hahn RT, Devereux RB, Post MR, Hackett NR, Foster T, Grasso TM, Lesser ML, Isom OW, Crystal RG. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999;100:468-474.
14. Hedman M, Muona K, Hedman A, Kivelä A, Syvänne M, Eränen J, Rantala A, Stjernvall J, Nieminen MS, Hartikainen J, Ylä-Herttuala S. Eight-year safety followup of coronary artery disease patients after local intracoronary VEGF gene transfer. Gene Ther 2009;16:629-634.
15. Rosengart TK, Bishawi MM, Halbreiner MS, Halbreiner MS, Fakhoury M, Finnin E, Hollmann C, Shroyer AL, Crystal RG. Long-term follow-up of a phase 1 trial of angiogenic gene therapy using direct intramyocardial administration of an adenoviral vector expressing the VEGF121 cDNA for the treatment of diffuse coronary artery disease. Hum Gene Ther 2013;24:203-208.
16. Muona K, Makinen K, Hedman M, Manninen H, Yla-Herttuala S. 10-year safety follow-up in patients with local VEGF gene transfer to ischemic lower limb. Gene Ther 2012;19:392-395.
17. Hassinen I, Hartikainen J, Hedman A, Kivelä A, Saraste A, Knuuti J, Husso M, Mussalo H, Hedman M, Toivonen P, Heikura T, Ylä-Herttuala S, Adenoviral intramyocardial VEGF-D transfer increases myocardial perfusion in refractory angina patients. Circulation 2015;132:A11987.
18. Kaminsky SM, Quach L, Chen S, Pierre-Destine L, Graaf B, Van De, Monette S, Rosenberg JB, Sondhi D, Hackett NR, Crystal RG. Safety of direct administration of ADVEGFALL6A+, an adenovirus vector expressing a CDNA/genomic hybrid of human vascular endothelial growth factors, to the ischemic myocardium of rats. Mol Ther 2013;21:S143.
19. Henry TD, Grines CL, Watkins MW, Dib N, Barbeau G, Moreadith R, Andrasfay T, Engler RL. Effects of Ad5FGF-4 in patients with angina. An analysis of pooled data from the AGENT-3 and AGENT-4 Trials. J Am Coll Cardiol 2007;50:1038-1046.
20. Kaski JC, Consuegra-Sanchez L. Evaluation of ASPIRE trial: a Phase III pivotal registration trial, using intracoronary administration of Generx (Ad5FGF4) to treat patients with recurrent angina pectoris. Expert Opin Biol Ther 2013;13:1749-1753.
21. Yang ZJ, Zhang YR, Chen B, Zhang SL, Jia EZ, Wang LS, Zhu TB, Li CJ, Wang H, Huang J, Cao KJ, Ma WZ, Wu B, Wang LS, Wu CT. Phase i clinical trial on intracoronary administration of Ad-hHGF treating severe coronary artery disease. Mol Biol Rep 2009;36:1323-1329.
22. Kim JS, Hwang HY, Cho KR, Park EA, Lee W, Paeng JC, Lee DS, Kim HK, Sohn DW, Kim KB. Intramyocardial transfer of hepatocyte growth factor as an adjunct to CABG: phase I clinical study. Gene Ther 2013;20:717-722.
23. Belch J, Hiatt WR, Baumgartner I, Driver IV, Nikol S, Norgren L, Belle EV. Effect of fibroblast growth factor NV1FGF on amputation and death: A randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet 2011;377:1929-1937.
24. Kilian EG, Sadoni S, Vicol C, Kelly R, Hulst K. V, Schwaiger M, Kupatt C, Boekstegers P, Pillai R, Channon K, Hetzer R, Reichart B. Myocardial transfection of hypoxia inducible factor-1alpha via an adenoviral vector during coronary artery bypass grafting. - A multicenter phase I and safety study. Circ J 2010;74:916-924.
25. Greenberg B, Butler J, Felker GM, Ponikowski P, Voors AA, Desai AS, Barnard D, Bouchard A, Jaski B, Lyon AR, Pogoda JM, Rudy JJ, Zsebo KM. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): A randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet 2016;387:1178-1186.
26. Chung ES, Miller L, Patel AN, Anderson RD, Mendelsohn FO, Traverse J, Silver KH, Shin J, Ewald G, Farr MJ, Anwaruddin S, Plat F, Fisher SJ, AuWerter AT, Pastore JM, Aras R, Penn MS. Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor- 1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial. Eur Heart J 2015;36:2228-2238.
27. Halonen PJ, Nurro J, Kuivanen A, Ylä-Herttuala S. Current gene therapy trials for vascular diseases. Expert Opin Biol Ther 2014;14:327-336.
28. Karpanen T, Bry M, Ollila HM, Seppanen-Laakso T, Liimatta E, Leskinen H, Kivela R, Helkamaa T, Merentie M, Jeltsch M, Paavonen K, Andersson LC, Mervaala E, Hassinen IE, Yla-Herttuala S, Orešič M, Alitalo K. Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy. Circ Res 2008;103:1018-1026.
29. Lahteenvuo JE, Lahteenvuo MT, Kivela A, Rosenlew C, Falkevall A, Klar J, Heikura T, Rissanen TT, Vahakangas E, Korpisalo P, Enholm B, Carmeliet P, Alitalo K, Eriksson U, Yla-Herttuala S. Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-1- and neuropilin receptor-1-dependent mechanisms. Circulation 2009;119:845-856.
30. Criqui MH, Aboyans V. Epidemiology of Peripheral Artery Disease. Circ Res 2015;116:1509-1526.
31. Tendera M, Aboyans V, Bartelink M-L, Baumgartner I, Clément D, Collet J-P, Cremonesi A, Carlo MD, Erbel R, Fowkes FGR, Heras M, Kownator S, Minar E, Ostergren J, Poldermans D, Riambau V, Roffi M, Röther J, Sievert H, Sambeek M, Van Zeller T, Bax J, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases. Eur Heart J 2011;32:2851-2906.
32. Deev RV, Bozo IY, Mzhavanadze ND, Voronov DA, Gavrilenko AV, Chervyakov YV, Staroverov IN, Kalinin RE, Shvalb PG, Isaev AA. pCMV-vegf165 intramuscular gene transfer is an effective method of treatment for patients with chronic lower limb ischemia. J Cardiovasc Pharmacol Ther 2015;20:473-482.
33. Hammer A, Steiner S. Gene therapy for therapeutic angiogenesis in peripheral arterial disease - a systematic review and meta-analysis of randomized, controlled trials. Vasa 2013;42:331-339.
34. Makinen K, Manninen H, Hedman M, Matsi P, Mussalo H, Alhava E, Yla-Herttuala S. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther 2002;6:127-133.
35. Kusumanto YH, Weel V. V, Mulder NH, Smit AJ, Dungen JJAM. V D, Hooymans JMM, Sluiter WJ, Tio RA, Quax PHA, Gans ROB, Dullaart RPF, Hospers GAP. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum Gene Ther 2006;17:683-691.
36. Rajagopalan S, Mohler IIIER, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK, Blebea J, Macko J, Kessler PD, Rasmussen HS, Annex BH. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent cl. Circulation 2003;108:1933-1938.
37. Grossman PM, Mendelsohn F, Henry TD, Hermiller JB, Litt M, Saucedo JF, Weiss RJ, Kandzari DE, Kleiman N, Anderson RD, Gottlieb D, Karlsberg R, Snell J, Rocha-Singh K. Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease. Am Heart J 2007;153:874-880.
38. Creager MA, Olin JW, Belch JJF, Moneta GL, Henry TD, Rajagopalan S, Annex BH, Hiatt WR. Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication. Circulation 2011;124:1765-1773.
39. Nikol S, Baumgartner I, Belle EV, Diehm C, Visoná A, Capogrossi MC, Ferreira-Maldent N, Gallino A, Wyatt MG, Wijesinghe LD, Fusari M, Stephan D, Emmerich J, Pompilio G, Vermassen F, Pham E, Grek V, Coleman M, Meyer F. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther 2008;16:972-978.
40. Yonemitsu Y, Matsumoto T, Maehara Y, Gene Therapy for peripheral arterial disease using Sendai Virus vector: from preclinical studies to the Phase I/IIa clinical trial. In: Nagai, ed. Sendai Virus Vector. Japan: Springer; 2013. p185-199.
41. Powell RJ, Simons M, Mendelsohn FO, Daniel G, Henry TD, Koga M, Morishita R, Annex BH. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 2008;118:58-65.
42. Shigematsu H, Yasuda K, Iwai T, Sasajima T, Ishimaru S, Ohashi Y, Yamaguchi T, Ogihara T, Morishita R. Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther 2010;17:1152-1161.
43. Anghel A, Taranu G, Seclaman E, Rata A, Tamas L, Moldovan H, Ursoniu S, Samoila C, Ionac M, Popa-Wagner A. Safety of vascular endothelial and hepatocyte growth factor gene therapy in patients with critical limb ischemia. Curr Neurovasc Res 2011;8:183-189.
44. Dragneva G, Korpisalo P, Yla-Herttuala S. Promoting blood vessel growth in ischemic diseases: challenges in translating preclinical potential into clinical success. Dis Model Mech 2013;6:312-322.
45. Losordo DW, Vale PR, Hendel RC, Milliken CE, Fortuin FD, Cummings N, Schatz RA, Asahara T, Isner JM, Kuntz RE. Phase 1/2 placebo-controlled, doubleblind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002;105:2012-2018.
46. Laitinen M, Makinen K, Manninen H, Matsi P, Kossila M, Agrawal RS, Pakkanen T, Luoma JS, Viita H, Hartikainen J, Alhava E, Laakso M, Yla-Herttuala S. Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia. Hum Gene Ther 1998;9:1481-1486.
47. Puumalainen AM, Vapalahti M, Agrawal RS, Kossila M, Laukkanen J, Lehtolainen P, Viita H, Paljarvi L, Vanninen R, Yla-Herttuala S. Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum Gene Ther 1998;9:1769-1774.
48. Hedman M, Hartikainen J, Ylä-Herttuala S. Progress and prospects: hurdles to cardiovascular gene therapy clinical trials. Gene Ther 2011;18:743-749.
49. Katz MG, Fargnoli AS, Pritchette LA, Bridges CR. Gene delivery technologies for cardiac applications. Gene Ther 2012;19:659-669.
50. Henri O, Pouehe C, Houssari M, Galas L, Nicol L, Edwards-Lévy F, Henry J-P, Dumesnil A, Boukhalfa I, Banquet S, Schapman D, Thuillez C, Richard V, Mulder P, Brakenhielm E. Selective stimulation of cardiac lymphangiogenesis reduces myocardial edema and fibrosis leading to improved cardiac function following myocardial infarction. Circulation 2016;133:1484-1497.